Related Experiment Videos
Lipid screening in HIV-infected veterans
P Todd Korthuis1, Steven M Asch, Henry D Anaya
1Oregon Health and Sciences University, Portland 97239-3098, USA. korthuis@ohsu.edu
Journal of Acquired Immune Deficiency Syndromes (1999)
|April 13, 2004
Summary
Lipid screening is recommended for patients on protease inhibitors (PIs). Only 59% of HIV-infected veterans received timely lipid screening, highlighting a gap in care for those with IVDU or unknown HIV risk.
Area of Science:
- Medical research
- Public health
- HIV/AIDS management
Background:
- Lipid screening is crucial for patients using protease inhibitors (PIs).
- Adherence to lipid screening guidelines among HIV-infected patients on PIs is not well-documented.
Purpose of the Study:
- To assess the rate of lipid screening in HIV-infected veterans receiving PIs.
- To identify patient and facility factors associated with timely lipid screening.
Main Methods:
- Data from the Veterans Administration Immunology Case Registry (1999-2001) were analyzed.
- Associations between lipid screening and patient/facility characteristics were estimated using adjusted models.
Main Results:
- 59% of 4065 patients on PIs received lipid screening within 6 months of treatment initiation.
- Screening was more frequent in urban areas, and among diabetic or hyperlipidemic patients.
- Screening was less frequent in patients with a history of intravenous drug use (IVDU) or unknown HIV risk.
Conclusions:
- A significant proportion of patients on PIs do not receive timely lipid screening.
- Interventions are needed to improve lipid screening rates, especially for high-risk groups (IVDU, unknown HIV risk) and in nonurban settings.